Comparative efficacy of Palbociclib and Everolimus with aromatase inhibitors in second line treatment of HR and HER2 negative metastatic breast cancer

Abstract Background Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) often develops resistance to endocrine therapy (ET), necessitating targeted therapies like Palbociclib (CDK4/6 inhibitor) and Everolimus (mTOR inhibitor). Thi...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Nadia Najafizade, Shadi Zarei, Mohammadreza Elhaie, Mahnaz Roayaei
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Springer 2025-12-01
Edice:	Discover Oncology
Témata:	Breast neoplasms Hormone receptor positive breast cancer Metastatic breast cancer Palbociclib Everolimus
On-line přístup:	https://doi.org/10.1007/s12672-025-04330-0
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!